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ABSTRACT
Background: Polymerase chain reaction (PCR) methods play an essential role in providing data 
related to diagnosis, monitoring and treatment of hepatitis C virus (HCV) infection. EIA results are 
reported as “reactive” or “non reactive” and EIA S/CO ratio may also be reported as “high” or “low.” 
This study aimed to evaluate the performance of a real-time RT-PCR and assess whether there is 
relationship between S/CO and PCR results. Study Design and Methods: Sera from blood donors 
were analyzed by Enzyme-Linked Immunosorbent Assay (ELISA) and RT-PCR assay to detect HCV 
infection. Results: The RT-PCR assay to genotypes 1a/b showed an acceptable linear response in se-
rial dilutions. The samples were divided into two groups based on their serological results: group A – 
S/CO ratio < 3 (60 samples) and group B – S/CO ratio > 3 (41 samples). Viral loads were confi rmed 
positive in group B samples in 90%, and in group A samples were confi rmed positive in only 13% by 
RT-PCR. Conclusion: The methodology used was able to detect the presence of RNA-HCV genotype 
I in 90% of the samples serologically positive in group B. All negative samples were sent to search for 
other genotypes of HCV (genotypes 2-6) and were confi rmed as negative. These data suggests that 
these negative samples may have HCV RNA viral load below the detection limit of our test (310 IU/
mL), or a false positive result in serological test, or spontaneous viral clearance occurred.
Keywords: HCV, HCV genotype 1, real-time PCR, ELISA, RNA extraction. 
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INTRODUCTION
The hepatitis C virus (HCV), discovered in 
1989, is the major causative agent of hepatitis 
non-A, non-B. This virus, which belongs to the 
family Flaviviridae and has a genome constitut-
ed by a positive single-strand RNA, is transmit-
ted parenterally, showing a high incidence in 
hemophiliacs hemodialysis patients, injecting 
drug users, and patients with post-transfusion 
hepatitis.1,2 
Hepatitis C infection has had high preva-
lence in Brazilian population mainly in the 
south region.3,4 According to literature,5 more 
than half of infected patients (about 70 to 
85%) develop chronic hepatitis, some of them 
(10% to 20%) progressing to cirrhosis and 
hepatocellular carcinoma in a period of 10 
to 15 years. Because hepatitis C has high po-
tential to become chronic, it is considered a 
serious public health problem, being estimat-
ed that there are 170 million people infected 
worldwide.6 Currently, hepatitis C is the lead-
ing cause of liver transplants in USA.7 
Diagnosis of hepatitis C is primarily based 
on serological tests, with detection of antibodies 
to HCV by methods based on ELISA8 or chemi-
luminescence.9 The HCV antibody is not a neu-
tralizing one and generally is present in patients 
with viremia; it can be a marker of past infection, 
because it tends to remain indefi nitely in patients 
who had hepatitis C and progressed to healing.10 
In cases of an inconclusive result in the screen-
ing test, complementary tests are necessary. Until 
recently, this confi rmation could only be achieved 
by recombinant immunoblot assay (RIBA).10,11 
These techniques (ELISA, chemiluminescence, 
and immunoblot) have a window-period limita-
tion, which can last 70-82 days, considerably re-
ducing its usefulness for diagnosis of cases of acute 
HCV infection.8 Currently, the PCR test that de-
tects the viral RNA have added many advantages 
for diagnosis of hepatitis C.12,13 This test is useful 
for: diagnosis of acute infection (seroconversion), 
diagnosis of infection in patients with negative or 
undetermined serology tests, evaluate the possi-
bility of false-positive serological results, and also 
allow quantifi cation of viral RNA.4 
Este é um artigo Open Access sob a licença de CC BY-NC-ND
148
Another molecular technique that has been used to 
differentiate HCV subtypes is genotyping. The molecular 
characterization of genotypes and sub-genotypes of HCV 
is particularly important in guiding the response to treat-
ment and disease prognosis.5,6,14 There are 11 major geno-
types of HCV and 23 subtypes. The prevalence of geno-
types of HCV varies according to geographic region. In 
Brazil, the genotypes 1, 2, and 3 are the most often found.6 
According to literature, patients infected with genotypes 
2 and 3 respond better to treatment than those infected 
with genotype 1. Genotype 1 patients have a less effective 
response to treatment and a high viral load.15,16 Hepatitis 
C treatment is based on therapy with interferon-α and 
Ribavirin. It is a very long treatment with an average du-
ration of 48 to 72 weeks,17 with a high cost (between U$ 
12,000 and U$ 15,000 U.S. dollars per patient per year in 
the U.S). Besides being an expensive and prolonged treat-
ment, it has a successful rate of 45-80% depending on viral 
genotype,17,18 probably because only few HCV genotypes 
respond quick and completely to this therapy. The fact is 
that there is a strong relationship between genotype of 
the virus and effectiveness of treatment increase the im-
portance of genotyping the HCV. Genotyping assess the 
patient’s prognosis providing important information, so 
that the clinician can tailor the treatment to the case.
PCR 
PCR depends on the ability to alternately denature (melt) 
double-stranded DNA molecules and renature (anneal) 
complementary single strands in a controlled fashion. The 
second requirement for PCR is the use of synthetic oligo-
nucleotides at least18–20 nucleotides long with a defi ned se-
quence. Such synthetic nucleotides can be readily produced 
with automated instruments based on the standard reac-
tion scheme. A typical PCR procedure begins by heat-de-
naturation of a DNA sample into single strands. Next, two 
synthetic oligonucleotides complementary to the 3 ends of 
the target DNA segment of interest are added in great ex-
cess to the denatured DNA, and the temperature is lowered 
to 50-60° C. These specifi c oligonucleotides, which are at a 
very high concentration, will hybridize with their comple-
mentary sequences in the DNA sample, whereas the long 
strands of the sample DNA remain apart because of their 
low concentration. The hybridized oligonucleotides then 
serve as primers for DNA chain synthesis in the presence 
of deoxynucleotides (dNTPs) and a temperature-resistant 
DNA polymerase, such as that from Thermus aquaticus (a 
bacteria that lives in hot springs). This enzyme, called Taq 
polymerase, can remain active even after being heated to 
95° C and can extend the primers at temperatures up to 
72° C. When synthesis is complete, the whole mixture is 
then heated to 95° C to melt the newly formed DNA du-
plexes. After temperature is lowered again, another cycle of 
synthesis takes place because excess primer is still present. 
Repeated cycles of melting (heating) and synthesis (cool-
ing) quickly amplify the sequence of interest. At each cycle, 
the number of sequence copies between the primer sites 
is doubled; therefore, the desired sequence increases expo-
nentially — about a million-fold after 20 cycles — whereas 
all other sequences in the original DNA sample remain un-
amplifi ed.
Use of the PCR technique 
The development of DNA segments amplifi cation using 
PCR opened vast prospects for analysis of genes, diagnosis 
of genetic diseases, and detection of infectious agents, such 
as cytomegalovirus, hepatitis B and C viruses, herpes vi-
rus simplex, rubella virus, human immunodefi ciency virus 
(HIV), Chlamydia trachomatis, Helicobacter pylori, Pneu-
mocystis jirovecii (formerly P. carinii), and Mycobacterium 
tuberculosis. 
The advancement of science on the understanding of 
genes brought into the laboratory routine genetics tools 
for the diagnosis in molecular level. In the line of genetic 
diseases, the continuing development of new protocols has 
enabled the detection of small changes in DNA sequence; 
for example, in cystic fi brosis. 
Other applications especially for the PCR is the clon-
ing of a DNA specifi c fragment, which may be a gene and 
knowledge of coding DNA (cDNA) obtained from the mol-
ecule of RNA, which allows the study of gene expression. 
Finally, PCR has great potential in forensic medicine. 
Its sensitivity makes it possible to use a very small sample 
(minimum traces of blood and tissues that could contain 
the remains of only one cell) and still get a “DNA fi nger-
print” of the person from which the sample was collected 
and can therefore make comparisons with those obtained 
from victims and/or a criminal suspect.19
Real-time PCR 
The ability to monitor real-time PCR has revolutionized the 
process of DNA and RNA fragment quantifi cation. Real-
time PCR makes nucleic acid quantifi cation with greater 
accuracy and reproducibility, as well as its predictive values 
during the exponential phase of the reaction. The point that 
detects the cycle in which the reaction reaches the threshold 
of exponential phase is called Cycle Threshold (CT). In real-
time PCR, each round of amplifi cation leads to the emission 
of a ﬂ uorescent signal and the number of signals per cycle 
is proportional to the amount of HCV-RNA in the starting 
sample.20 This allows the accurate and reproducible quanti-
fi cation based on ﬂ uorescence. 
The issue of ﬂ uorescent compounds generates a signal 
that increases in direct proportion to quantity of PCR prod-
uct. Therefore, the values of ﬂ uorescence are recorded dur-
ing every cycle and represent the amount of product ampli-
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fi ed. The most used compounds are ﬂ uorescent SYBR Green 
and TaqMan probe. 
Real-time PCR requires an instrumentation platform 
that consists of a thermal cycler, computer, optics for ﬂ uo-
rescence excitation and emission collection, and data acqui-
sition and analysis software.
The aim of this work is to evaluate real-time PCR One-
Step method to detect hepatitis C virus genotype 1 and try 
to establish a relationship between S/CO ratio and PCR test 
results.
MATERIAL AND METHODS
Clinical specimens
From October 2008 to August 2009, blood samples were ob-
tained from 101 blood donors with positive antibody screen-
ing for hepatitis C (ELISA – EIA-3; Biomeriéux Co.) and 
10 donors with negative screening. All blood samples were 
negative for other tests mandatory in blood bank screening 
(ELISA).
Design of primers and probe (FAM – Assay with 
ﬂ uorescent marker/MGB – Minor Groove Binder)
The primers and probe for real-time PCR used in this study 
were designed in primer express software (Applied Biosys-
tems) based on HCV sequence. The sequences of primers 
HCV are the following: 5´-CGGGAGAGCCATAGTGGT – 3’ 
(HCV 1F, position: 130-147); 5´-CGCGACCCAACACTACTC 
– 3´(HCV 1R, position: 256-273). The probe sequence was 
selected within primer pair HCV 1F and HCV 1R and cit-
ed at position 149-169, which was designed to be perfectly 
complementary to the target sequence in 5´-NCR of HCV 
genome. The following is the probe sequence: FAM – TGCG-
GAACCGGTGAGTACACC – MGB (HCV 1P). Both prim-
ers and probe were suspended in DEPC Water and stored at 
-20° C. 
RNA extraction
For preparation of total RNA from human sera, we used the 
QIAamp Viral RNA kit according to manufacturer’s instruc-
tions (QIAGEN, Courtaboeuf, France). In brief, 140 µL of 
serum was incubated with 560 µL of lysis buffer containing 
chaotropic salts and carrier RNA for 10 min at room tem-
perature. After the addition of 560 µL of ethanol, the precip-
itated RNA was applied onto a silica-based spin column for 
purifi cation and was fi nally eluted with 60 µL of QIAamp 
elution buffer. 
Reverse transcription and ampliﬁ cation
The reverse transcription was performed using a methodol-
ogy one-step with TaqMan Probes Reaction Mix, containing 
0,5 µL Superscript III RT/Platinum Taq Mix; 12,5 µL (2x Re-
action Mix); 0,5 µL Forward primer (10 uM); 0,5 µL Reverse 
primer (10 µM); 0,1 µL Fluorogenic probe (10 uM); 0,5 µL 
RNase Out; <10 µL Template (1 pg to 1 µg total RNA) and 
DEPC-treated water to 20 µL.
Amplifi cation was performed in 20 µL reaction mixture 
containing TaqMan Universal PCR Master Mix, UNG, 
DNTPs, a passive reference (6-carboxy-rhodamine; 
ROX). Standard cycling program was: 15 min hold at 
50° C for cDNA synthesis temperature may range from 
42-60° C; 2 min hold at 95° C; 40 cycles of: 15 s at 95° 
C; 30 s at 60° C.
Enzyme Linked Immunosorbent Assay Screening 
(ELISA)
Testing for HCV antibodies was performed with a third 
generation enzyme immunoassay (EIA-3; Biomeriéux 
Co.) following the manufacturer’s instructions. S/CO 
ratio (S = sample ratio and CO = Cutoff ratio) was de-
termined for all blood samples and, based on this, we 
created two groups: group A in which S/CO ratio was < 
3, and group B in which S/CO ratio was > 3. This algo-
rithm was developed in order to establish the relation-
ship between S/CO ratio and the probability RT-PCR 
been positive.21
RESULTS
Linear range and limit of detection
Once the standard curve had been calculated, the software 
automatically quantifi ed the number of HCV RNA, report-
ing the Ct of the sample to the Ct of the standard curve. The 
correlation coeffi cient (R2) of the analysis was above 0.99 
for all the experiments, from a commercial standard sample 
(positive control) with a pre-established number of copies. 
The standard curve was made using different concentra-
tions (ranging from 310 to 310.000 IU/mL or 2,5 to 5,5 Log) 
showed in Figure 1. 
Figure 1: Standard curve of the HCV RNA concentration (log) 
in serial dilutions vs. cycle number (Ct). Each dot represents 
the results of triplicate PCR amplification for each dilution.
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DISCUSSION
Although the risk of transfusion-transmitted HCV has pro-
gressively decreased during the past few decades, thanks to 
introduction of several preventive measures such as careful 
selection of blood donors, enhanced donor questioning for 
eligibility and refi nement in blood donation screening, and 
stimulation to donor fi delity, the implementation of NAT 
together with the existing serological assays can reduce the 
residual risk of recipient’s infection by shortening the win-
dow period (temporal gap spanning from the time of infec-
tion to seroconversion). During this period, an infected do-
nor may harbor large amounts of infection viral particles in 
absence of serological markers and/or signs and symptoms 
of an ongoing infection. Due to the relatively long seronega-
tive window period for HCV infection, about 82 days if us-
ing the third generation antibody test available, in this study 
we showed the importance of testing for viral RNA, which 
enables detection 10 days after infection and leads to safe 
transfusions.
Polymerase chain reaction (PCR) is a powerful tool 
for detection of minimal amounts of nucleic acids. Due 
to the exponential amplification of the target sequence, it 
has exquisite sensitivity. Few copies of any transcript can 
be readily detected, even against a high background of 
unrelated nucleic acid. The establishment of PCR-based 
detection methods has provided the basis for rapid and 
reliable detection of viral nucleic acids in the clinical set-
ting. It was shown that monitoring virus load and kinet-
ics of virus proliferation have prognostic relevance for 
the course of disease and clinical outcome.22-27 The avail-
ability of quantitative virus detection tests is therefore of 
paramount importance for the clinical management of 
virus infections. 
Most assays described for the detection of viral DNA or 
RNA is based on the use of hydrolysis probes, also referred 
to as TaqMan. The probes bind to the target strand between 
PCR primers. They are dually labeled with a ﬂ uorescence re-
porter dye attached to the 5´-end, a quencher dye, attached 
to the 3´-end. When the reporter molecule on TaqMan 
probe is stimulated, an appropriate light source to emit ﬂ uo-
rescence, the energy is transferred to the quencher, thereby 
suppressing the emission of ﬂ uorescence by the reporter.28 
During PCR, when DNA polymerase extends the primers, 
the hybridized probes are split by the enzyme 5´exonuclease 
activity and the corresponding quencher and reporter mol-
ecules are separated. The energy transferred to the quencher 
molecule is thus abrogated, and the reporter starts emitting 
ﬂ uorescence, which can be measured at the end of each ex-
tension step.29 In well established assays, there is a linear cor-
relation between the number of released reporter molecules 
and the number of amplicons synthesized during each PCR 
cycle. This correlation serves as a basis for calculation of ini-
tial copy number of target transcript.
Figure 4: Samples with S/CO ratio &gt;3.
In order to compare the reproducibility between our test 
and a commercial test, we studied 24 samples by another 
PCR method (Amplicor Monitor HCV RNA assay®, Ver-
sion 2.0, Roche Diagnostics, Meylan, France). All positive 
samples were confi rmed positive in both methods, showing 
100% reproducibility (Figure 2).
In group A samples, from a total of 60 samples, only eight 
(13%) were positive by real-time PCR test (Figure 3).
Out of 41 positive samples with S/CO ratio > 3, 37 sam-
ples (90%) were confi rmed positive by RT-PCR test in group 
B, while four samples were negative (Figure 4).
Figure 3: Samples with&nbsp; S/CO ratio &lt; 3.
Figure 2: Comparison between Real Time RT-PCR vs. 
Amplicor Roche.
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This method shows several advantages, such as fast ex-
ecution and reduced risk of contamination, due to the lack 
of post-PCR processing steps. TaqMan technology requires 
specifi c conditions for the choice of primers and probe: They 
should have a Tm difference of 10° C, the absence of gua-
nosine at the 5´amino probe sequence and an amplifi cation 
length ideally under 100bp. The amplicon length, together 
with the restrictive conditions of primers and probe designs, 
does not facilitate the assay use with RNA viruses, in particu-
lar, due to their genetic variability. The development of DNA 
probes with conjugated minor groove binder (MGB) groups 
has allowed the use of shorter probes in hybridization-based 
assays. Interestingly, the design of an array within the rare 
conserved region of 5´- UTR of HCV was facilitated by the 
use of a 3´- MGB probe. 
In our laboratory, the TaqMan quantitative HCV assay 
showed linearity over a range of 3,1x102 to 3,1x105 IU/mL. 
Thus, serum samples with a viral load higher than 310.000 
IU/mL have to be diluted. The detection limit of this test 
can vary as noted in other publications that showed an esti-
mated limit at 550 IU/mL30,31 because different methods are 
used for determining RNA concentration.32-35
Trani et al.36 also used the technique of one-step real-
time PCR with MGB probe to detect avian inﬂ uenza viruses. 
The linear correlation (R2) of that study was 0.99, the same 
found in our study, showing high sensitivity of test. Arruda 
et al.,37 even using a different technology, SYBR Green tech-
nique, to evaluate patients with HTLV I/II infection, made a 
standard curve using serial dilutions of plasmid in concen-
trations from 100 to 105, getting R2 = 0,89.
Wang Lu-Nan et al.,38 through technology Roche Cobas 
Amplicor method, evaluated R2 for detection of HCV and 
was able to detect a range of 600 to 850,000 IU/mL, unlike 
the data presented by us, demonstrating that the technique 
used by our laboratory was more sensitive in detecting low 
levels of viral load.
EIA results are reported as “reactive” or “nonreactive” 
and EIA signal to cutoff (S/CO) ratio may also be reported 
as “high” or “low.” EIA S/CO ratio is a comparison of the 
optical density of the patient’s positive EIA result to the op-
tical density of the laboratory’s positive EIA control. If the 
ratio is high > 3.0 using the most widely employed diagnos-
tic kits, ELISA, the positive predictive value (that the patient 
truly has HCV antibody in the blood) of the patient’s result 
is high, still emphasize the importance of confi rming these 
results using PCR or RIBA.
In our results, we could observe that 90% of the group 
B samples (S/CO ratio > 3) was positive in the PCR test, 
confi rming the serological tests, but four samples did not 
confi rm the results obtained by ELISA; in contrast with 
group A, in sixty samples of group B (S/CO ratio < 3) only 
8 were confi rmed as positive by RT-PCR. The reason for the 
difference in results between the techniques is not clear. We 
can suggest that these patients have low viral load in which 
was not possible to detect the RNA, as our test showed the 
detection limit of 310 IU/mL. Moreover, there are data from 
literature showing that some patients, who developed anti-
HCV, had clearance of viral RNA during acute infection.39,40 
However, this subject need to be more explored and studied. 
On the other hand, our service use a safety margin of 10% 
on cut-off, meaning that the samples negative by RT-PCR 
and positive by ELISA, could be within this margin, con-
fi rming the data obtained by RT-PCR.
In other studies in Brazil, samples repeatedly positive to 
EIA-2 with S/CO ratio > 3 were associated with 100% of 
true-positive results and have around 92% of positivity for 
HCV RNA by RT-PCR.41
Hence, through our study, we conclude that the One-
Step methodology was easy to apply, adding agility to the 
PCR methods with reliable results, and we can state that 
there is a strong positive relationship between S/CO and the 
results presented by real-time PCR in HCV detection.
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